

1 Excess mortality in the general population versus Veterans Healthcare System during the first
2 year of the COVID-19 pandemic in the United States

3
4 Daniel M. Weinberger,^{1,2} Liam Rose^{3,4}, Christopher Rentsch^{2,5,8}, Steven M. Asch,^{3,4} Jesse
5 Columbo,^{6,7} Joseph King, Jr.,^{2,8} Caroline Korves,⁶ Brian P. Lucas,^{6,7} Cynthia Taub,⁹
6 Yinong Young-Xu,⁶ Anita Vashi,^{3,4,10} Louise Davies,^{6,7} Amy C. Justice^{1,2,8}

7
8
9 1 Yale School of Public Health, New Haven, CT

10 2 Department of Veterans Affairs Connecticut Healthcare System, West Haven, CT

11 3 Department of Veterans Affairs Medical Center, Palo Alto, CA

12 4 Stanford School of Medicine, Palo Alto, CA

13 5 London School of Hygiene & Tropical Medicine, London, England

14 6 Department of Veterans Affairs Medical Center, White River Junction, VT

15 7 Geisel School of Medicine at Dartmouth, Hanover, NH

16 8 Yale School of Medicine, New Haven, CT

17 9 Dartmouth Hitchcock Medical Center, Lebanon, NH

18 10 Department of Emergency Medicine, University of California, San Francisco

19
20
21 Word count: 3000

22 Figures: 3

23 Tables: 2

24 Online supplement

25
26 Acknowledgement: This material is based upon work supported by the Department of Veterans
27 Affairs, Veterans Health Administration, Office of Research and Development, Health Services
28 Research and Development.

29
30 Disclaimer: The views expressed in this article are those of the authors and do not necessarily
31 reflect the position or policy of the Department of Veterans Affairs or the United States
32 government

33
34 Conflicts of interest: DMW has received consulting fees for work unrelated to this manuscript
35 from Pfizer, Merck, GSK, Affinivax, and Matrivax, and is Principal Investigator on research
36 grants from Pfizer and Merck to Yale University for work unrelated to this manuscript. CK has
37 been an investigator on projects with research grants from Pfizer and Sanofi Pasteur for work
38 unrelated to this manuscript. The other authors declare no conflicts.

41 ABSTRACT

42 *Importance* The COVID-19 pandemic had a substantial impact on the overall rate of death in the
43 United States during the first year. It is unclear whether access to comprehensive medical care,
44 such as through the VA healthcare system, altered death rates compared to the US population.

45
46 *Objective:* Quantify the increase in death rates during the first year of the COVID-19 pandemic
47 in the general US population and among individuals who receive comprehensive medical care
48 through the Department of Veterans Affairs (VA).

49
50 *Design:* Analysis of changes in all-cause death rates by quarter, stratified by age, sex
51 race/ethnicity, and region, based on individual-level data. Hierarchical regression models were fit
52 in a Bayesian setting. Standardized rates were used for comparison between populations.

53
54 *Setting and participants:* General population of the United States, enrollees in the VA, and active
55 users of VA healthcare.

56
57 *Exposure and main outcome:* Changes in rates of death from any cause during the COVID-19
58 pandemic in 2020 compared to previous years.

59
60 *Results* Sharp increases were apparent across all of the adult age groups (25 years and older) in
61 both the general US population and the VA populations. Across all of 2020, the relative increase
62 in death rates was similar in the general US population (RR: 1.20 (95% CI: 1.17, 1.22)), VA
63 enrollees (RR: 1.20 (95% CI: 1.14, 1.29)), and VA active users (RR: 1.19 (95% CI: 1.14, 1.26)).
64 Because the pre-pandemic standardized mortality rates were higher in the VA populations prior
65 to the pandemic, the absolute rates of excess mortality were higher in the VA populations.

66
67 *Conclusions and Relevance:* Despite access to comprehensive medical care, active users of the
68 VA had similar relative mortality increases from all causes compared with the general US
69 population. Factors that influenced baseline rates of death and that mitigated viral transmission in
70 the community are more likely to have influenced the impact of the pandemic.

71
72
73

74 INTRODUCTION

75 During the first year of the COVID-19 pandemic, there was a substantial increase in the rate of
76 death in the United States (US) [1]. This increase, particularly in older adults, was largely a
77 consequence of infection with SARS-CoV-2 [2]. However, the impact of the pandemic varied
78 substantially across subpopulations. Rates of death related to COVID-19 were higher among
79 Black and Hispanic populations compared to White populations, among men compared with
80 women, and among older adults compared with younger individuals [3]. These disparities were
81 influenced by a number of factors including social determinants of health (e.g., employment
82 type, household composition), differing comorbidities, systemic differences in access to
83 healthcare, and biological differences in immune responses by age and sex.

84
85 Less understood is the role that the health care system response played in exacerbating or
86 mitigating disparities. A more robust healthcare system might have mitigated some of the worst
87 outcomes of the pandemic in the United States, either by better managing existing chronic health
88 conditions, minimizing disruptions in care, or by an integrated response to the pandemic itself
89 [4]. The US Department of Veterans Affairs (VA) provides comprehensive care nationally for
90 Veterans of the armed forces. Comparing the impacts of the COVID-19 pandemic among VA
91 users to the general US population could shed light on the role that health care played in
92 producing variations in outcomes during the pandemic.

93
94 Previous reports show that death rates among those who typically received care in the VA
95 system were less affected than the general US population during the COVID-19 pandemic,
96 despite higher rates of comorbidities [5–7]. However, Veterans enrolled in VA care also differ
97 from the general US population in age, sex, racial/ethnic composition, and geographic
98 distribution, and each of these factors has been associated with mortality rates in general and
99 deaths rates due to COVID-19 specifically [8–10]. Now that individual-level mortality data are
100 available for both populations, it is possible to make appropriate comparisons by accounting for
101 their differing demographic characteristics.

102
103 The aim of this analysis was to quantify excess all-cause deaths during the first nine months of
104 the COVID-19 pandemic in Veterans enrolled in the VA system compared with the general US
105 population and to obtain standardized overall estimates of excess deaths, adjusted for age, sex,
106 race/ethnicity, and region.

107 108 METHODS

109 110 *Overview*

111 The analyses focused on deaths among adults aged 25 years and older in three different
112 populations: VA enrollees, VA active users, and the general US population. Data were obtained
113 from the National Center for Health Statistics (NCHS) and from the VA for deaths occurring

114 between January 1, 2014 and December 31, 2020. Time series were created by counting the
115 number of deaths by age group, sex, race/ethnicity, year, quarter, and census region (West,
116 South, Midwest, Northeast). A model was fit to quarterly data from 2014-2019 (pre-pandemic)
117 and then extrapolated to 2020. Excess deaths and rate ratios were calculated by comparing the
118 observed number of deaths with the expected number of deaths.'

119

120 **Data Sources and Definitions**

121

122 *National Center for Health Statistics (NCHS)*. Individual-level data representing all deaths in the
123 US were obtained from the NCHS through a data use agreement that allowed for the sharing of
124 geographic location of the deaths [11]. The individual-level data, except for geographic region,
125 are publicly available and can be downloaded from the NCHS website [11]. These vital statistics
126 data have detailed information on the deceased individual including age (years), sex,
127 race/ethnicity, state and county of residence, and the underlying and contributing causes of death
128 (coded using the International Classification of Diseases, 10th revision).

129

130 Population size data for the general US population, collected by the US Census Bureau, were
131 obtained from the bridged race files (Vintage 2020) produced by the NCHS. These data are
132 available at the annual scale (July 1 estimates). To estimate population size for each stratum by
133 quarter, we used linear interpolation.

134

135 *Department of Veterans Affairs (VA)*.

136

137 The VA enrollee population includes approximately 10.9 million individuals enrolled in VA
138 health care: 9.2 million Veterans and 1.7 million who are family members of disabled Veterans
139 [12]. The population of the VA system is commonly defined as either all enrollees or those who
140 actively use the VA system. The majority of enrollees have another form of health insurance,
141 with Medicare being the most common among those aged 65 years or older [13]. The baseline
142 comorbidities and rates of deaths vary between these populations, and as such we include two
143 definitions in our analysis (i.e., “VA enrollees”, “VA active users”).

144

145 VA enrollees were defined as any individuals eligible for care, either paid for or provided by the
146 VA. VA active users were individuals with at least one diagnosis in their VA electronic health
147 record in the two years prior to each time point, indicating at least one clinical encounter within
148 the VA [14]. The VA active user cohort is dynamic, with the population determined by activity
149 in the previous two year from each time point.

150

151 Population size data for the VA populations were obtained by querying the Assistant Deputy
152 Under Secretary for Health (ADUSH) Enrollment Files for each fiscal year.

153

154 *Definitions*

155 These analyses focused on deaths among adults aged 25 years and older. The three populations
156 are nested within each other (VA active users are also VA enrollees; VA enrollees are also part
157 of the general US population). The analyses focused on deaths among adults aged 25 years and
158 older because there are very few Veterans under the age of 25 (1.3% of Veterans).

159

160 For each population, we used the same definitions for creating subgroups:

- 161 ● Age group: (25-44, 45-64, 65-74, 75-84, 85+ years)
- 162 ● Sex (male/female)
- 163 ● Race/Ethnicity: non-Hispanic White; Non-Hispanic Black or African American;
164 Hispanic; American Indian/Native Alaskan; Asian, Native Hawaiian and Other Pacific
165 Islander. These groups were chosen to align with population size data available from the
166 National Center for Health Statistics (NCHS) [16].
- 167 ● Quarter (Jan-Mar, Apr-Jun, Jul-Sep, Oct-Dec)
- 168 ● Census region (Northeast, South, West, Midwest) [15],

169

170 **Statistical analysis:**

171 *Model to generate a baseline*

172 The goal for the model was to generate an expected number of deaths by month and subgroup
173 based on pre-pandemic quarterly data from the preceding six pre-pandemic years (2014-2019)
174 and then extrapolate to each quarter in 2020. Because the pandemic began in earnest in the US in
175 March 2020, the first quarter of 2020 includes both pandemic and pre-pandemic months and is
176 therefore not used for model fitting. Excess deaths and rate ratios are calculated by comparing
177 the observed number of deaths with the expected number of deaths based on the model.

178 Observed and modeled values were combined over subgroups to obtain summary estimates. We
179 used a hierarchical regression model fit in a Bayesian setting using the INLA packaged in R
180 (*Supplementary Methods*).

181

182 *Standardized death rates*

183 For comparisons between the different populations, we use death rates standardized by age, sex,
184 race/ethnicity, and region, using direct standardization. The population of VA enrollees who
185 have non-missing data on race/ethnicity was used as the standard population. Both the observed
186 and expected deaths rates were standardized, and the ratio of these standardized values provides
187 a mortality rate ratio adjusted for population structure.

188

189 *Individual-level analysis*

190 We leveraged the full patient-level data from VA active users to compare estimates of excess
191 mortality using the Poisson model described above, which are fit to aggregate data, with a
192 patient-level Cox proportional hazards model, fit to individual-level data (*Supplementary*
193 *Methods*).

194

195 *Availability of code and data*

196 Code used for all analyses can be found at [https://github.com/VA-](https://github.com/VA-CareDisruptions/VA_CDC_death_comparison)
197 [CareDisruptions/VA_CDC_death_comparison](https://github.com/VA-CareDisruptions/VA_CDC_death_comparison). All analyses were completed in R [17]. Data on
198 US mortality, with the exception of state/region, can be obtained from
199 https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm. For additional variables,
200 including geography, a data use agreement with NCHS is required. VA data and the analytic data
201 sets used for this study can be made available to researchers with a VA IRB approved study
202 protocol and data use agreement. Information is available at <https://www.virec.research.va.gov>
203 or contact the VA Information Resource Center at VIREC@va.gov.

204

205 RESULTS

206 *Demographics and baseline death rates*

207 The demographics of the VA population differed from those of the general US population in
208 several important ways. The VA population was predominantly male, older than the general US
209 population, and had a larger proportion who were Black or Hispanic (**Table 1**). Expected death
210 rates were generally higher in the VA enrollees than the general US population (2520 vs 930
211 deaths per 100,000) and higher still in active users of VA healthcare (2910 deaths per 100,000)
212 (**Table 2**). Even after standardizing the death rates by age, sex, race/ethnicity, and region, the
213 expected death rate among the VA active users was ~25% higher than in the general US
214 population (2160 deaths/100,000 in the US population vs 2730 among VA active users (**Table**
215 **2**).

216

217 *Relative and absolute increases in rates of death in 2020*

218 There were sharp differences between rates of observed and expected deaths due to any cause
219 starting in the 2nd quarter of 2020 (April onwards). These increases were apparent across all of
220 the adult age groups (25 years and older) in both the general US population and the VA
221 populations (**Figure 1**). There were subtle differences in the magnitude of the relative increases
222 during the first wave of the pandemic (2020 Q2), with a larger increase in the general US
223 population than either of the VA populations. (**Figure 2A**) However, these differences were
224 largely due to differences in the geographic and demographic makeup of the populations, which
225 were resolved by standardization (**Figure 2B, Figure S1**). Across all of 2020, the relative
226 increase in death rates during 2020 was similar in the general US population (RR: 1.20 (95%CI:
227 1.17, 1.22)), VA enrollees (RR: 1.20 (95%CI: 1.14, 1.29)), and VA active users (RR: 1.19 (95%
228 CI: 1.14, 1.26)). Because the pre-pandemic standardized mortality rates were higher in the VA
229 populations prior to the pandemic, the absolute rates of excess mortality were higher in the VA
230 population despite the similar relative increases in all three populations (**Figures 2 and 3, Table**
231 **2**).

232

233 *Comparison of excess death rates by age, sex, and race/ethnicity*

234 While women comprised a small fraction of the VA population, the relative increase in rates of
235 death during 2020 was more notable for women compared to men among VA enrollees,
236 particularly among younger women (**Figure S2**). These estimates are based on small numbers
237 and should be interpreted with caution. The relative increase in deaths was smaller in the White
238 population than in other racial/ethnic groups, and this was consistent between the general US
239 population and the VA populations (**Figure S3**).

240

241 *Rates of excess deaths vs recorded COVID deaths*

242

243 Overall, in 2020 there were 200 excess deaths/100,000 people in the US population (95%CI:
244 170, 220). During the same period, there were 170 deaths/100,000 people that were recorded as
245 having COVID-19 as the underlying or contributing cause (**Table 2**). This suggests that ~85% of
246 the increase in the death rate was directly attributable to COVID-19 (170 COVID-19 deaths/200
247 total excess deaths). Access to specific causes of death were not available for the VA population
248 unless the individual received a test for SARS-CoV-2 within the VA system.

249

250 *Individual-level analysis*

251 Estimates of the relative increase in death rates during 2020 among VA active users was similar
252 between the Poisson model (RR 1.18, 95% CI 1.15-1.22) and the patient-level Cox model (RR
253 1.17, 95% CI 1.15-1.20). There was also no meaningful difference in the estimates by quarter
254 (**Table S1**).

255

256 DISCUSSION

257 In this study, we find that after adjusting for differences in age, sex, race/ethnicity, and region,
258 the relative increase in rates of death during the first nine months of the COVID-19 pandemic
259 were similar between the general US population and enrollees and users of the VA healthcare
260 system. The absolute pre-pandemic death rate was higher among the VA populations, and this
261 translated to higher absolute excess death rates among Veterans, despite the similar relative
262 increases.

263

264 A key question is whether having access to a unified healthcare system through the VA affected
265 the risk of death during the first phase of the pandemic. Our analysis demonstrates that the
266 COVID-19 pandemic effectively acted as a multiplier on the baseline death rates. Therefore, if
267 individuals receiving care in the VA system had a lower risk of death than if they had not had
268 access to care, then the pre-pandemic death rate might have been even higher, and the rates of
269 excess deaths might have been higher as well. The higher baseline rates of death in the VA
270 population were expected because those in the VA system, particularly the active users, are
271 enriched for those seeking regular medical care, who might be more likely to have comorbidities,
272 which is consistent with the results of prior investigators [18]. To evaluate whether the VA

273 reduces baseline rates of death, it would be necessary to evaluate death rates among individuals
274 outside of the VA system with similar comorbid conditions.

275
276 There are also reasons to expect that access to unified healthcare might not be impactful. Early in
277 the pandemic, vaccines and effective treatments were not yet available, so access to healthcare
278 for COVID-19 might not have been a major driver of outcomes. In the first year, most of the
279 excess deaths were likely due to COVID; moving forward into subsequent years of the
280 pandemic, when there were more treatment and prevention strategies, having access to quality
281 care could have a larger effect. Additionally, while processes of care tend to be better in the VA
282 system [19,20], access to care, wait times for procedures, and outcomes are similar in the VA
283 and in non-VA healthcare systems [21,22].

284
285 The increase in death rates during the pandemic differed by racial/ethnic group, and this was
286 consistent between the three populations. Previous work demonstrated that once hospitalized,
287 Black and White Veterans had similar rates of death due to COVID-19 [23]. This suggests
288 differences in the impact of the COVID-19 pandemic are due to other factors, primarily the rate
289 of infection in the different groups. The risk of infection varied by race/ethnicity and region [24],
290 and larger household size was also associated with greater infection risk [25].

291
292 While the numbers were small, the data suggested that the increase in deaths during the
293 pandemic was more acute for women in the VA system, and particular young women. Women
294 make up a small percentage of the overall VA population and are more predominantly people of
295 color. They could differ from women in the general population in terms of their occupations and
296 exposures to the virus. The female population was too small to evaluate interactions between
297 race/ethnicity and gender.

298
299 Measuring excess mortality has advantages and disadvantages as an analytical approach for
300 understanding the impact of the pandemic. By evaluating the overall increase in rates of death,
301 regardless of cause, issues related to variations in viral testing and difference in cause-of-death
302 coding practices are mitigated. The downside is that there is not a perfect correlation between
303 excess deaths and deaths caused by COVID-19. The magnitude of the excess deaths could result
304 directly from deaths caused by the virus, or they could indirectly result from a number of factors
305 including avoidance of emergency care services, disruptions to routine or emergency care,
306 changes in rates of other infectious diseases (e.g., the disappearance of influenza in 2020), and
307 changes in rates of violent crime and overdoses that might have been related to pandemic
308 disruptions [2]. The magnitude of the increase in death rates in the US was similar to the
309 magnitude of recorded COVID-19 deaths (170 recorded COVID-19 deaths per 100,000 vs 200
310 overall excess deaths), suggesting that much of the increase is directly related to the virus.
311 Modeling studies that make use of the time series of deaths suggest that most of the increase in
312 death rates in older adults was directly related to the virus, based on the timing and trajectory of
313 the increases in all-cause deaths [2]. It is likely that many of the deaths in younger adult age

314 groups were not directly related to the virus, so other indirect factors, including worsening
315 mental health and increases in substance abuse, are likely to have a larger relative impact in
316 younger age groups [2]. Analysis of the data using Poisson models and individual-level hazard
317 models yielded similar estimates given adjustment for the same set of baseline covariates, as
318 would be expected. Future work could focus on further developing the individual-level models to
319 account for additional indicators of underlying health status. Further, longer term mortality
320 consequences of delays in treatment for older individuals with comorbid diseases may take
321 longer to be observed.

322
323 These analyses have some important limitations. Race/ethnicity data were missing for 24% of
324 VA enrollees and 7-14% of active users. The data for these individuals is effectively dropped
325 when calculating the standardized rates. If the race/ethnicity data are missing at random, this
326 would not introduce bias into the estimates. However, individuals with missing race/ethnicity
327 information tend to be less dependent on VA care and are more likely to be non-White [26].
328 Therefore, we likely under-count the impact of the pandemic on non-White populations. While
329 we are able to standardize comparisons by age, sex, race/ethnicity, and region, we did not have
330 individual-level data on comorbidities in the general US population. Therefore, differences in the
331 prevalence of comorbidities between Veterans and general US populations that do not correlate
332 with the adjusted factors could confound the comparisons [27]. Estimates of excess deaths
333 depend on the statistical modeling, including trend and seasonal components, being correctly
334 specified. We used a hierarchical model, which generally will generate a more stable model for
335 sparse groups, but these types of models can also introduce bias for individual groups. This could
336 lead to over- or under-estimation of the trend for some groups, causing inaccurate estimates of
337 excess deaths for subgroups.

338
339 In conclusion, using detailed mortality records, we find that the relative impact of the COVID-19
340 pandemic on all-cause mortality was similar in the general US population and among users of the
341 VA healthcare system. This suggests that access to comprehensive healthcare alone was not
342 sufficient to mitigate the worst impacts of the virus during the first 10 months of the COVID-19
343 pandemic.

344
345

346
347

	US Population	VA Enrollees	VA active users
n	328,329,953	10,939,936	7,047,401
Mean Age (SD)	39.0 (23.1)	61.0 (18.2)	62.2 (17.2)
Age Group (%)			
Under 25	103,323,542 (31.5%)	195,689 (1.9%)	61,186 (1%)
25-44	87,678,128 (26.7%)	2,108,249 (20.1%)	1,184,766 (18.1%)
45-64	83,291,548 (25.4%)	3,052,556 (29.0%)	1,900,716 (29.0%)
65-74	31,471,344 (9.6%)	2,825,582 (26.9%)	1,972,179 (30.1%)
75-84	15,965,924 (4.9%)	1,380,960 (13.1%)	873,952 (13.3%)
85+	6,599,467 (2.0%)	946,160 (9.0%)	565,774 (8.6%)
Race (%)			
White	200,897,980 (61.2%)	6,045,752 (55.3%)	4,348,260 (61.7%)
Black	43,319,362 (13.2%)	1,383,616 (12.6%)	1,087,871 (15.4%)
Hispanic	60,404,487 (18.4%)	596,537 (5.5%)	430,393 (6.1%)
American Indian	2,753,041 (0.8%)	61,684 (0.5%)	43,446 (0.6%)
Asian/Hawaiian/ Pacific Islander	20,955,083 (6.4%)	180,311 (1.6%)	119,279 (1.7%)
Missing race	-	2,672,036 (24.4%)	1,018,152 (14.4%)
Sex (%)			
M	161,692,336 (49.2%)	9,393,350 (85.9%)	6,010,777 (87.9%)
F	166,637,617 (50.8%)	1,230,007 (11.2%)	618,829 (9.1%)

The three populations are fully nested: VA active users are included within enrollees, which are included within the US population. The race/ethnicity categories are mutually exclusive. The VA demographic data are for the start of fiscal year 2019, which ran October 2018-September 2019

349
350

Table 2.			
	United States	VA enrollees	VA active users
All-cause Deaths/100,000*			
Expected 2020 Q2-4	930 (910, 960)	2520 (2360, 2670)	2910 (2770, 3050)
Observed 2020 Q2-4	1130	3022	3441
Excess incidence	200 (170, 220)	500 (360, 660)	530 (95%CI:390, 680)
Rate ratio	1.22 (1.18, 1.25)	1.20 (1.13, 1.28)	1.18 (1.12, 1.24)
Reported COVID deaths/100,000	170	-	-
Deaths/100,000* people (standardized to VA enrollee population)			
Expected 2020 Q2-4	2160 (2130, 2200)	2360 (2210, 2500)	2730 (2590, 2860)
Observed 2020 Q2-4	2588	2842	3256
Excess incidence	430 (390, 460)	480 (350, 630)	530 (400, 670)
Rate ratio	1.20 (1.17, 1.22)	1.20 (1.14, 1.29)	1.19 (1.14, 1.26)
* All mortality rates calculated as deaths per 100,000 people age 25 and above during 2020 Q2-Q4. Expected incidence and excess incidence are rounded to the nearest 10.			

351
352

353

Table S1. Estimated rate ratio from individual-level and ecological models fit to data on VA active users					
Model type	IRR/HR Overall	IRR/HR Q1	IRR/HR Q2	IRR/HR Q3	IRR/HR Q4
Patient (Cox)	1.17 (1.15, 1.20)	1.02 (0.99, 1.05)	1.15 (1.12, 1.18)	1.19 (1.16, 1.22)	1.35 (1.32, 1.39)
Ecologic (Poisson)	1.18 (1.15, 1.22)	1.00 (0.96, 1.04)	1.10 (1.06, 1.15)	1.15 (1.10, 1.20)	1.29 (1.24, 1.35)

354

355

356




Figure 1. Observed and expected rates over time by age group among the general US population and among enrollees of the VA. The Black line with the shaded area indicates the fitted values (up through 2019) and predicted values (for 2020), while the colored lines show the observed incidence by quarter.

357

358

359

360
361
362
363
364




Fig 2: Trajectory of the rate ratio for the US, VA enrollees, and VA active users, calculated using (A) the raw mortality rates or (B) the mortality rates standardized by age, sex, race/ethnicity, and region. The closer alignment for the standardized plot on the right suggests that any differences on the left panel are related to demographic differences.

365

366




Fig 3. Observed mortality rates (open symbols) and expected mortality rates (closed symbols) in the US population, VA enrollees, and VA active users, stratified by age. The slope of the line indicates the relative increase during the pandemic (the rate ratio). Mortality rates are standardized based on the sex, race/ethnicity, region and distribution of the 65-79 year old VA enrollee population

367

368

369




Fig S1: Standardized rate ratio by quarter in 2020 (observed/expected), stratified by age and region, among White men.

371




Fig S2. Observed mortality rates (open symbols) and expected mortality rates (closed symbols) in the US population, VA enrollees, and VA active users, stratified by age and sex. Slope of the line indicates the relative increase during the pandemic. Mortality rates are standardized based on the region and race/ethnicity distribution of the 65-74 year old VA enrollee population

372

373

374




Fig S3. Observed mortality mortality rates (open symbols) and expected mortality rates (closed symbols) in the US population, VA enrollees, and VA active users, stratified by race/ethnicity. Slope of the line indicates the relative increase during the pandemic. Mortality rates are standardized by age, sex, region, and race/ethnicity to the VA enrollee population.

375

376

377 SUPPLEMENTARY TEXT

378 *Supplementary Methods*

379

380 *Model details*

381 Data in any given subgroup are sparse, making it difficult to fit separate models for each
382 subgroup (as was done in previous work [28]). Instead, we used a hierarchical Bayesian analysis
383 approach. With this approach, we fit a model to disaggregated data, but parameters were
384 estimated hierarchically so information was shared between strata. The model adjusted for
385 seasonality using categorical variables for quarter, adjusted for linear time trends, and uses a
386 population offset to adjust for the size of the at-risk population. An AR(1) random intercept was
387 included to capture unexplained variability in the data that was common across the different
388 strata. The model for the number of deaths in age group i , race/ethnicity group j , sex k , region r ,
389 and time t was:

390

391

$$Y_{ijkrt} \sim \text{Poisson}(\lambda_{ijkrt})$$

392

393 $\log(\lambda_{ijkrt}) = \alpha_{ijk} + \beta_{1,ijk} * \text{time} + \beta_{2,ijk} * \text{qtr2} + \beta_{3,ijk} * \text{qtr3} + \beta_{4,ijk} * \text{qtr4} + \phi_t$

394

395 The intercept for each subgroup is given as

396 $\alpha_{ijk} = a_0 + b_{0,i} + c_{0,j} + d_{0,k} + \psi_{ijk}$

397

398 The trend and effect of seasonality for each subgroup is given as

399 For $N\{1:4\}$: $\beta_{N,ijk} = a_N + b_{N,i} + c_{N,j} + d_{N,k}$

400

401 ϕ_t is an AR(1) random intercept, which captures unexplained temporal variation that is shared
402 across the different subgroups. a_x , b_x , c_x , d_x represent the contributions to the intercept, slope and
403 quarterly effects by age group (b), race/ethnicity group (c), and sex (d). A separate intercept
404 (α_{ijk}) was estimated for each region, but the time trends and seasonal effects ($\beta_{N,ijk}$) were shared
405 across regions. These models were fit using the INLA package in R, which uses approximate
406 Bayesian inference. Samples from the joint posterior distribution were obtained using the
407 `inla.posterior.sample()` function. Samples were combined across subgroups for calculating
408 summary measures and uncertainty intervals.

409

410 The a_N are assigned weakly informative priors ($N(0,1)$); the b_N , c_N , and d_N have shrinkage priors
411 ($N(0, \tau_m)$) and use the ‘Z-model’ formulation for random effects in INLA. Models were fit
412 separately to the time series for the different populations (e.g., US population, VA active users).

413

414 *Individual-level analysis*

415 We leveraged the full patient-level data from VA active users to compare estimates of excess
416 mortality using the Poisson model described above, which are fit to aggregate data, with a
417 patient-level Cox proportional hazards model, fit to individual-level data (Supplementary
418 Methods). To reduce computational burden, we limited the pre-pandemic time period in this
419 post-hoc analysis to 2 years (i.e., 2018-2019) for both the individual-level and aggregate models,
420 and a linear trend was not included due to the short baseline period. The Cox model was
421 specified using the same variables as the Poisson models and used current age as the time-scale.

422

423

424

425

426 REFERENCE

427

428 1. Woolf SH, Chapman DA, Sabo RT, Zimmerman EB. Excess Deaths From COVID-19 and
429 Other Causes in the US, March 1, 2020, to January 2, 2021. JAMA [Internet]. 2021; .
430 Available from: <http://dx.doi.org/10.1001/jama.2021.5199>

431 2. Lee W-E, Park SW, Weinberger DM, et al. Direct and indirect mortality impacts of the
432 COVID-19 pandemic in the US, March 2020-April 2021. medRxiv [Internet]. 2022; .
433 Available from: <http://dx.doi.org/10.1101/2022.02.10.22270721>

- 434 3. Truman BI, Chang M-H, Moonesinghe R. Provisional COVID-19 Age-Adjusted Death
435 Rates, by Race and Ethnicity - United States, 2020-2021. *MMWR Morb Mortal Wkly Rep.*
436 **2022**; 71(17):601–605.
- 437 4. Galvani AP, Parpia AS, Pandey A, et al. Universal healthcare as pandemic preparedness:
438 The lives and costs that could have been saved during the COVID-19 pandemic. *Proc Natl*
439 *Acad Sci U S A.* **2022**; 119(25):e2200536119.
- 440 5. Feyman Y, Auty SG, Tenso K, Strombotne KL, Legler A, Griffith KN. County-level impact of
441 the COVID-19 Pandemic on excess mortality among U.S. veterans: A population-based
442 study. *The Lancet Regional Health - Americas.* **2022**; 5:100093.
- 443 6. Lukowsky LR, Der-Martirosian C, Dobalian A. Disparities in Excess, All-Cause Mortality
444 among Black, Hispanic, and White Veterans at the U.S. Department of Veterans Affairs
445 during the COVID-19 Pandemic. *Int J Environ Res Public Health* [Internet]. **2022**; 19(4).
446 Available from: <http://dx.doi.org/10.3390/ijerph19042368>
- 447 7. Ioannou GN, Ferguson JM, O'Hare AM, et al. Changes in the associations of race and
448 rurality with SARS-CoV-2 infection, mortality, and case fatality in the United States from
449 February 2020 to March 2021: A population-based cohort study. *PLoS Med.* **2021**;
450 18(10):e1003807.
- 451 8. Carethers JM. Insights into disparities observed with COVID-19. *J Intern Med.* **2021**;
452 289(4):463–473.
- 453 9. Haitao T, Vermunt JV, Abeykoon J, et al. COVID-19 and Sex Differences: Mechanisms and
454 Biomarkers. *Mayo Clin Proc.* **2020**; 95(10):2189–2203.
- 455 10. Gross CP, Essien UR, Pasha S, Gross JR, Wang S-Y, Nunez-Smith M. Racial and Ethnic
456 Disparities in Population-Level Covid-19 Mortality. *J Gen Intern Med.* **2020**; 35(10):3097–
457 3099.
- 458 11. Public use data file documentation [Internet]. 2021 [cited 2022 Sep 2]. Available from:
459 https://www.cdc.gov/nchs/nvss/mortality_public_use_data.htm
- 460 12. Website [Internet]. Available from: <https://www.va.gov/budget/products.asp>
- 461 13. [No title] [Internet]. [cited 2022 Aug 2]. Available from:
462 [https://www.va.gov/VHASTRATEGY/SOE2021/2021_Enrollee_Data_Findings_Report-](https://www.va.gov/VHASTRATEGY/SOE2021/2021_Enrollee_Data_Findings_Report-508_Compliant.pdf)
463 [508_Compliant.pdf](https://www.va.gov/VHASTRATEGY/SOE2021/2021_Enrollee_Data_Findings_Report-508_Compliant.pdf)
- 464 14. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Patterns of COVID-19 testing and mortality by
465 race and ethnicity among United States veterans: A nationwide cohort study. *PLoS Med.*
466 *Public Library of Science (PLoS)*; **2020**; 17(9):e1003379.
- 467 15. [No title] [Internet]. [cited 2022 Aug 2]. Available from:
468 https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf
- 469 16. U.S. Census Populations With Bridged Race Categories [Internet]. 2022 [cited 2022 Aug 2].
470 Available from: https://www.cdc.gov/nchs/nvss/bridged_race.htm
- 471 17. Ripley BD. The R project in statistical computing. *MSOR connect. Educational*
472 *Development Unit, University of Greenwich*; **2001**; 1(1):23–25.

- 473 18. Hoerster KD, Lehavot K, Simpson T, McFall M, Reiber G, Nelson KM. Health and Health
474 Behavior Differences: U.S. Military, Veteran, and Civilian Men. *Am J Prev Med.* **2012**;
475 43(5):483–489.
- 476 19. Anhang Price R, Sloss EM, Cefalu M, Farmer CM, Hussey PS. Comparing Quality of Care
477 in Veterans Affairs and Non-Veterans Affairs Settings. *J Gen Intern Med.* **2018**;
478 33(10):1631–1638.
- 479 20. Asch SM, McGlynn EA, Hogan MM, et al. Comparison of Quality of Care for Patients in the
480 Veterans Health Administration and Patients in a National Sample. *Ann Intern Med.*
481 *American College of Physicians*; **2004**; 141(12):938–945.
- 482 21. Trivedi AN, Matula S, Miake-Lye I, Glassman PA, Shekelle P, Asch S. Systematic review:
483 comparison of the quality of medical care in Veterans Affairs and non-Veterans Affairs
484 settings. *Med Care.* **2011**; 49(1):76–88.
- 485 22. Penn M, Bhatnagar S, Kuy S, et al. Comparison of Wait Times for New Patients Between
486 the Private Sector and United States Department of Veterans Affairs Medical Centers.
487 *JAMA Netw Open.* **2019**; 2(1):e187096.
- 488 23. Sundaram SS, Melquist S, Kalgotra P, et al. Impact of age, sex, race, and regionality on
489 major clinical outcomes of COVID-19 in hospitalized patients in the United States. *BMC*
490 *Infect Dis.* **2022**; 22(1):659.
- 491 24. Ferguson JM, Justice AC, Osborne TF, Magid HSA, Purnell AL, Rentsch CT. Geographic
492 and temporal variation in racial and ethnic disparities in SARS-CoV-2 positivity between
493 February 2020 and August 2021 in the United States. *Sci Rep.* **2022**; 12(1):273.
- 494 25. Ferguson JM, Mitchell-Miland C, Shahoumian TA, et al. Temporal variation in individual
495 social risk factors associated with testing positive for SARS-CoV-2 among veterans in the
496 veterans health administration. *Ann Epidemiol.* **2022**; 73:22–29.
- 497 26. Peltzman T, Rice K, Jones KT, Washington DL, Shiner B. Optimizing Data on Race and
498 Ethnicity for Veterans Affairs Patients. *Mil Med.* **2022**; 187(7–8):e955–e962.
- 499 27. Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are Patients at Veterans Affairs Medical
500 Centers Sicker? [Internet]. *Archives of Internal Medicine.* 2000. p. 3252. Available from:
501 <http://dx.doi.org/10.1001/archinte.160.21.3252>
- 502 28. Weinberger DM, Chen J, Cohen T, et al. Estimation of excess deaths associated with the
503 COVID-19 pandemic in the United States, March to May 2020. *JAMA Intern Med.* *American*
504 *Medical Association (AMA)*; **2020**; 180(10):1336–1344.